VIP152 Is a Selective CDK9 Inhibitor with Pre-clinical In Vitro and In Vivo Efficacy in Chronic Lymphocytic Leukemia

In taking a multi-omic approach, scientists have demonstrated that CDK9 inhibition with VIP152 disrupted the highly ordered assembly of the transcriptional machinery, thereby promoting cellular stress and inevitable cell death.